It was a busy and exciting month for OCRA’s policy team and advocates from all across the country. OCRA’s 2024 Spring Advocacy Day took place on March 20, during which 140 advocates met with their Members of Congress and urged them to support increased funding for education and research programs focused on ovarian and related … Continued
OCRA’s Advocates are off to a running start this year with help from our largest Advocate Leader cohort in program history, at 125 participants representing 39 states and 111 congressional districts. Together with the OCRA policy team, Advocate Leaders are working to advance crucial legislative goals, including expanding federal funding of ovarian and other gynecologic cancer … Continued
Ovarian Cancer Research Alliance is pleased to welcome our 2024 cohort of Advocate Leaders, the biggest ever for our organization with a total of 125 participants. This year’s group, which comprises 43 new participants and 82 returnees, represents 39 states, including the new additions of Nevada and North Dakota. “We are so excited to get … Continued
Welcome to OCRA’s Advocate’s Corner, a new monthly series to keep you updated on how our Advocate Leaders and policy team are working on behalf of the ovarian and gynecologic cancer community. OCRA’s Advocates are beginning 2024 with great momentum. Here’s a look at our most impactful achievements in 2023: As the largest organization advocating … Continued
We took meaningful steps in the fight against ovarian and related gynecologic cancers this year, and we couldn’t have done it without your support. Join me for a look at this year’s most important updates, and please stand with us alongside patients, survivors and loved ones, with hope and commitment to a future without ovarian … Continued
OCRA’s Fall Advocacy Day Drives Change A sea of teal washed over the Capitol when more than 70 advocates from 30 states met with over 120 Congressional offices to push for legislative initiatives, including Medicare coverage of life-saving tools such as genetic testing, during OCRA’s 2023 Fall Advocacy Day. “Advocacy Day is so important to … Continued
The voices of OCRA’s advocates were amplified by recent television coverage of this year’s Fall Advocacy Day, during which more than 70 people from 30 states met with over 120 Congressional offices to push for critical legislation and funding. Their efforts were broadcast to more than 105,000 viewers, helping to get the message out about the vital … Continued
A sea of teal washed over the Capitol when more than 70 advocates from 30 states met with over 120 Congressional offices to push for legislative initiatives, including Medicare coverage of life-saving tools such as genetic testing, during OCRA’s 2023 Fall Advocacy Day. Advocacy Day Photos Click to scroll through a full gallery of Advocacy … Continued
OCRA Announces Game-Changing Initiatives This month, OCRA announced a trio of initiatives that carry profound implications for ovarian cancer and related research and patient support: OCRA will expand its mission to include related gynecologic cancers, will create the first comprehensive ovarian and endometrial cancer registry, and will initiate a groundbreaking international data commons. Audra Moran, President and CEO of … Continued
Special Registration for National Conference Ends Thursday, August 31st OCRA’s Ovarian Cancer National Conference returns virtually on November 1st – 3rd with important updates on research, care, and resources from top experts in the field. Topics will include new treatment developments, symptom management, caregiver concerns, and more, with interactive sessions and opportunities to connect. Regular $75 registration begins … Continued
This action alert has now expired. This shortage of chemotherapy drugs, including cisplatin and carboplatin, has reached a serious level, impacting the treatment options available to some ovarian cancer patients. But you can help. In response, Representatives Ami Bera (D-CA), Mike Kelly (R-PA), Derek Kilmer (D-WA), and Brian Fitzpatrick (R-PA) have authored a Dear Colleague … Continued
As many are aware, the United States is currently experiencing a matter of great concern: an ongoing shortage of chemotherapy drugs that are essential in the treatment of ovarian cancer. The availability of these medications is of critical importance to patients and their families, and we understand the anxiety and uncertainty this shortage may cause. … Continued
Get email updates about research news, action alerts, and ways to join the fight.
